22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:23 , Oct 26, 2018 |  BC Week In Review  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
22:52 , Oct 25, 2018 |  BC Extra  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
14:54 , Sep 11, 2018 |  BC Extra  |  Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest FGF21 could help treat spinal cord damage associated with traumatic brain injury (TBI) and multiple sclerosis. In postmortem tissue samples from MS patients, levels of the FGF21 signaling marker...
14:37 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Additional Ph II data

Additional data from a double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 for 16 weeks...